Viz.ai and iCardio.ai Partner on Aortic Stenosis Detection Using Ultrasound Imaging and Artificial Intelligence

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with iCardio.ai, a developer of comprehensive artificial intelligence algorithms for ultrasound imaging. This collaboration aims to advance the rapid detection of aortic stenosis and to facilitate the triage of patients affected by this condition through the addition of iCardio.ai’s breakthrough ultrasound interpretation technology into a comprehensive Viz.ai care coordination solution.

“Our collaboration with iCardio.ai is a testament to our commitment to bringing the most cutting-edge AI solutions to healthcare,” said Steve Sweeny, vice president of business development and strategy at Viz.ai. “By pairing iCardio.ai’s innovative ultrasound interpretation AI with our comprehensive Viz.ai Cardio Suite™, we will be setting a new standard for patient care.”

The partnership follows iCardio.ai’s FDA Breakthrough Device designation for its aortic stenosis detection algorithm. Aortic stenosis impacts approximately 1.5 million Americans¹ and poses severe risks if untreated. With the ability to predict aortic stenosis from a single ultrasound clip, iCardio.ai’s technology enables precise screening in diverse settings such as primary care or outpatient clinics.

“As an interventional cardiologist, I am particularly excited about the potential to revolutionize upstream management of patients suffering from aortic stenosis. AI for automated detection of aortic stenosis will help expedite diagnosis and specialist referral for these patients, ultimately improving access to life-saving treatments and patient outcomes” says Dr. Aakriti Gupta, Interventional Cardiologist at Cedars-Sinai and Co-Founder of iCardio.ai

In combination with the Viz.ai Cardio Suite, this echo-based automated detection aims to facilitate earlier diagnosis and reduce healthcare disparities by providing a standardized tool deployable across various healthcare settings.

“Receiving Breakthrough Device designation by the FDA is a recognition of the innovative nature of our technology,” said Joseph Sokol, CEO & Co-Founder of iCardio.ai. “We are excited to team up with Viz.ai, whose solutions are used by clinicians in over 1,500 healthcare institutions, to enable better treatment pathways for millions of patients.”

¹ Thoenes et al, M. (2018, September). Patient screening for early detection of aortic stenosis (as)-review of current practice and future perspectives. Journal of thoracic disease. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196210/#r19

About iCardio.ai

iCardio.ai is a Los Angeles-based deep learning startup automating the interpretation of heart ultrasounds. iCardio.ai’s core AI products are trained on its proprietary dataset of over +200 million ultrasound images. In February of 2024, iCardio.ai received Breakthrough Designation by the FDA for its Aortic Stenosis screening tool. iCardio.ai has teamed with some of the largest Ultrasound vendors to deliver its technology to clinicians around the globe.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

‍